Myomo Inc (NYSEAMERICAN:MYO) was the target of a large decline in short interest during the month of September. As of September 28th, there was short interest totalling 1,019,452 shares, a decline of 0.5% from the September 14th total of 1,024,133 shares. Approximately 9.9% of the shares of the company are short sold. Based on an average daily volume of 106,739 shares, the short-interest ratio is presently 9.6 days.

Myomo stock opened at $1.92 on Friday. Myomo has a 12 month low of $1.74 and a 12 month high of $11.40.

Myomo (NYSEAMERICAN:MYO) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $0.63 million during the quarter, compared to analyst estimates of $0.62 million. Myomo had a negative net margin of 257.70% and a negative return on equity of 155.42%.

Institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC raised its holdings in Myomo by 243.9% in the 1st quarter. Citadel Advisors LLC now owns 40,861 shares of the company’s stock valued at $121,000 after acquiring an additional 28,981 shares in the last quarter. A.R.T. Advisors LLC acquired a new position in Myomo in the 1st quarter valued at approximately $277,000. Finally, Account Management LLC acquired a new position in Myomo in the 2nd quarter valued at approximately $312,000.

Several equities analysts have commented on the company. Zacks Investment Research cut Myomo from a “hold” rating to a “sell” rating in a report on Wednesday, September 26th. HC Wainwright set a $12.00 price target on Myomo and gave the company a “buy” rating in a report on Tuesday, August 14th.

Myomo Company Profile

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

See Also: Stock Split

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.